Bcl-2-targeted cancer therapeutics

Expert Opinion on Therapeutic Patents

Volumn 14, Issue 6, 2004, Pages 805-818

  Khorchid, Amani ^a   Beauparlant, Pierre ^a  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

Antimycin; Antisense; Apoptosis; Bcl 2; Bcl XL; BH3; BH3I 1; BH3I 2; Cancer; Chelerythrine; Gossypol; HA14 1; Oblimersen; Small molecule; Therapy; Tumour

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ANTIMYCIN A1; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CHELERYTHRINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FAS ANTIBODY; GOSSYPOL; HA 141; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; OBLIMERSEN; OLIGOMYCIN; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE C INHIBITOR; ROTENONE; STAUROSPORINE; TERPHENYL DERIVATIVE; TETROCARCIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; US 6548536;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER SURVIVAL; CARCINOGENESIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; FEVER; HUMAN; LETHARGY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; ONCOGENE; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; TUMOR MODEL;

EID: 3042842776     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.14.6.805     Document Type: Review

References (99)

1. SHI Y: Mechanisms of caspase activation and inhibition during apoptosis. Mol. Cell (2002) 9:459-470.
2. CORY S, ADAMS JM: The Bcl-2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer (2002) 2:647-656.
3. LETAI A, BASSIK M, WALENSKY L, SORCINELLI M, WEILER S, KORSMEYER S: Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell (2002) 2:183-192.
4. KINOSHITA T, YOKOTA T, ARAI K, MIYAJIMA A: Regulation of Bcl-2 expression by oncogenic Ras protein in hematopoietic cells. Oncogene (1995) 10:2207-2212.
5. LIU H, PERLMAN H, PAGLIARI LJ, POPE RM: Constitutively activated Akt-1 is vital for the survival of human monocyte-differentiated macrophages. Role of Mcl-1, independent of nuclear factor (NF)-κB, Bad, or caspase activation. J. Exp. Med. (2001) 194:113-126.
6. KITAMURA S, KONDO S, SHINOMURA Yet al.: Met/HGF receptor modulates bcl-w expression and inhibits apoptosis in human colorectal cancers. Br. J. Cancer (2000) 83:668-673.
7. NGAN BY, CHEN-LEVY Z, WEISS LM, WARNKE RA, CLEARY ML: Expression in non Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation. N. Engl. J. Med. (1988) 318:1638-1644.
8. LOPES DE, MENEZES DE, HUDON N, MCINTOSH N, MAYER LD: Molecular and pharmacokinetic properties associated with the therapeutics of Bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Clin. Cancer Res. (2000) 6:2891-2902.
9. GLEAVE M, TOLCHER A, MIYAKE H et al.: Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin. Cancer Res. (1999) 5:2891-2898.
10. KLASA RJ, BALLY MB, NG R, GOLDIE JH, GASCOYNE RD, WONG FM: Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin. Cancer Res. (2000) 6:2492-2500.
11. JANSEN B, SCHLAGBAUER-WADL H, BROWN BD et al.: Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat. Med. (1998) 4:232-234.
12. SCHLAGBAUER-WADL H, KLOSNER G, HEERE-RESS E et al.: Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice. J. Invest. Dermatol. (2000) 114:725-730.
13. SIMOES-WUSTA AP, OLIE RA, GAUTSCHI O et al.: Bcl-xl antisense treatment induces apoptosis in breast carcinoma cells. Int. J. Cancer (2000) 87:582-590.
14. CHI KN, WALLIS AE, LEE CH et al.: Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression. Breast Cancer Res. Treat. (2000) 63:199-212.
15. COTTER FE, JOHNSON P, HALL P et al.: Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene (1994) 9:3049-3055.
16. KUMAZAKI T, SASAKI M, NISHIYAMA M, TERANISHI Y, SUMIDA H, MITSUI Y: Effect of BCL-2 down-regulation on cellular life span. Biogerontology (2002) 3:291-300.
17. ACKERMANN EJ, TAYLOR JK, NARAYANA R, BENNETT CF.: The role of antiapoptotic Bcl-2 family members in endothelial apoptosis elucidated with antisense oligonucleotides. J. Biol. Chem. (1999) 274:11245-11252.
18. L expression sensitizes normal human keratinocytes and epithelial cells to apoptotic stimuli. Oncogene (1999) 18:4495-4504.
19. L antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages. J. Invest. Dermatol. (2002) 118:505-512.
20. L might be the crucial member of the Bcl-2 gene family in colorectal cancer. Dig. Dis. Sci. (1998) 43:2641-2648.
21. WILSON JW, NOSTRO MC, BALZI M et al.: Bcl-w expression in colorectal adenocarcinoma. Br. J. Cancer (2000) 82:178-185.
22. L and Bcl-2 expression in squamous cell carcinoma of the head and neck. Cancer (1999) 85:164-170.
23. L worsens the prognosis in pancreatic cancer. Ann. Surg. (1998) 228:780-787.
24. L. Am. J. Pathol. (1996) 149:795-803.
25. BAUER JJ, SESTERHENN IA, MOSTOFI FK, MCLEOD DG, SRIVASTAVA S, MOUL JW: Elevated levels of apoptosis regulator proteins p53 and Bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J. Urol. (1996) 156:1511-1516.
26. CERRONI L, SOYER HP, KERL H: Bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi. Am. J. Dematopathol. (1995) 17:7-11.
27. LAZARIDOU A, MIRAXTSI C, KORANTZIS J, ELEFTHERIADIS N, CHRISTAKIS JI: Simultaneous detection of BCL-2 protein, trisomy 12, retinoblastoma and P53 monoallelic gene deletions in B-cell chronic lymphocytic leukemia by fluorescence in situ hybridization (FISH): relation to disease status. Leuk. Lymphoma (2000) 36:503-512.
28. KARAKAS T, MAURER U, WEIDMANN E, MIETHING CC, HOELZER D, BERGMANN L: High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann. Oncol. (1998) 9:129-130.
29. MIKAMI T, YANAGISAWA N, BABA H, KOIKE M, OKAYASU I: Association of Bcl-2 protein expression with gallbladder carcinoma differentiation and progression and its relation to apoptosis. Cancer (1999) 85:318-325.
30. EID H, GULYAS M, GECZI L, BODROGI I, INSTITORIS E, BAK M: Expression of Bcl-2 in testicular carcinoma: correlation with tumor progression and MDR1/Pgp. Cancer (1998) 83:331-336.
31. RODRIGUEZ-PEREIRA C, SUAREZ-PENARANDA JM, BARROS F, SOBRIDO MJ, VAZQUEZ-SALVADO M, FORTEZA J: Analysis of 2 antiapoptotic factors in gliomas: bcl-2 over-expression and p53 mutations. Arch. Pathol. Lab. Med. (2001) 125:218-223.
32. BEALE PJ, ROGERS P, BOXALL F, SHARP SY, KELLAND LR: BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma. Br. J. Cancer (2000) 82:436-440.
33. HEERE-RESS E, THALLINGER C, LUCAS T et al: Bcl-X(L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy. Int. J. Cancer (2002) 99:29-34.
34. L in a human ovarian carcinoma cell line: paradoxic effects on chemosensitivity in vitro versus in vivo. Int. J. Cancer (2002) 97:858-863.
35. KITADA S, TAKAYAMA S, DE RIEL K, TANAKA S, REED JC: Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res. Dev. (1994) 4:71-79.
36. MIAYAKE H, TOLCHER A, GLEAVE ME. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 of oligodeoxynucleotides. J. Natl. Cancer Inst. (2000) 92:34-41.
37. L antisense sensitizes human colon cancer cell line to 5-fluorouracil. Jpn. J. Cancer Res. (2000) 91(8):825-32.
38. L down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity. Clin. Cancer Res. (2003) 9:2856-2865.
39. L antisense oligonucleotides chemosensitize human glioblastoma cells. Chemotherapy (2002) 48:189-195.
40. L in prostate cancer cells: effects of over-expression and down-regulation on chemosensitivity. Cancer Res. (2000) 60:6052-6060.
41. L underlies the molecular basis for resistance to staurosporine-induced apoptosis in PC-3 cells. Cancer Res. (2001) 61:1699-1706.
42. L. J. Biol. Chem. (Epub ahead of print).
43. WILSON WH, TERUYA-FELDSTEIN J, FEST T et al.: Relationship of p53, Bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood (1997) 89:601-609.
44. HERMINE O, HAIOUN C, LEPAGE E et al.: Prognostic significance of Bcl-2 protein expression in aggessive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood (1996) 87:265-272.
45. ELLEDGE RM, GREEN S, HOWES L et al.: Bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer a Southwest Oncology Group study. J. Clin. Oncol (1997) 15:1916-1922.
46. L, without alteration of p53 protein levels. Clin. Cancer Res. (1999) 5:2971-2977.
47. CROOKE ST: Progress in antisense technology. Ann. Rev. Med (2004) 55:61-95.
48. JANSEN B, ZANGEMEISTER-WITTKE U: Antisense therapy for cancer - the time of truth. Lancet Oncol. (2002) 3:672-683.
49. TAUCHI T, SUMI M, NAKAJIMA A et al.: BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells. Clin. Cancer Res. (2003) 9:4267-4273.
50. WEBB A, CUNNINGHAM D, COTTER F et al.: Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet (1997) 349:1137-1141.
51. WATERS JS, WEBB A, CUNNINGHAM D et al.: Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J. Clin. Oncol. (2000) 18:1812-1823.
52. JANSEN B, WACHECK V, HEERE-RESS E et al.: Chemosensitisation of malignant melanoma by Bcl-2 antisense therapy. Lancet (2000) 356:1728-1733.
53. WOOLDRIDGE JE, BALLAS Z, KRIEG AM, WEINER GJ: Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood (1997) 89:2994-2998.
54. WACHECK V, KREPLER C, STROMMER S et al.: Antitumor effect of G3139 Bcl-2 antisense oligonucleotide is independent of its immune stimulation by CpG motifs in SCID mice. Antisense Nucleic Acid Drug Dev. (2002) 12:359-367.
55. GUTIERREZ-PUENTE Y, TARI AM, FORD RJ et al.: Cellular pharmacology of P-ethoxy antisense oligonucleotides targeted to Bcl-2 in a follicular lymphoma cell line. Leuk. Lymphoma (2003) 44:1979-1985.
56. ZANGEMEISTER-WITTK U, SCHENKER T, LUEDKE GH, STAHEL RA. Synergistic cytotoxicity of the Bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br. J. Cancer (1998) 78:1035-1042
57. MORELLI S, DELIA D, CAPACCIOLI A et al.: The antisense Bcl-2-IgH transcript is an optimal target for synthetic oligonucleotides. Proc. Natl. Acad. Sci. USA (1997) 94:8150-8155.
58. S through the control of Bcl-X pre-mRNA splicing by antisense oligonucleotide. Nat. Biotechnol. (1999) 17:1097-1100.
59. L-bispecific antisense oligonucleotide against tumors of diverse histologic origins. J. Natl. Cancer Inst. (2001) 93:463-471.
60. L bispecific antisense oligonucleotide. Clin Cancer Res (2001) 7:1446-1451
61. L, epidermal growth factor receptor, and protein kinase A Type I causes potent antitumor, apoptotic, and antiangiogenic activity. Clin. Cancer Res. (2003) 9:866-871.
62. THALLINGER C, WOLSCHEK MF, WACHECK V et al.: Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model. J. Invest. Dermatol. (2003) 120:1081-1086.
63. FINNEGAN NM, CURTIN JF, PREVOST G, MORGAN B, COTTER TG: Induction of apoptosis in prostate carcinoma cells by BH3 peptides which inhibit Bak/Bcl-2 interactions. Br. J. Cancer (2001) 85:115-121.
64. WANG JL, ZHANG ZJ, CHOKSI S et al.: Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. (2000) 60:1498-1502.
65. RADETZKI S, KOHNE CH, VON HAEFEN C et al.: The apoptosis promoting Bcl-2 homologues Bak and Nbk/Bik overcome drug resistance in Mdr-1-negative and Mdr-1-overexpressing breast cancer cell lines. Oncogene (2002) 21:227-238.
66. TOMITA F, TAMAOKI T: Tetrocarcins, novel antitumor antibiotics. I. Producing organism, fermentation and antimicrobial activity. J. Antibiot. (1980) 33:946-950.
67. TAMAOKI T, KASAI M, SHIRAHATA K et al.: Tetrocarcins, novel antitumor antibiotics. II. Isolation, characterization and antitumor activity. J. Antibiot. (1980) 33:940-945.
68. MORIMOTO M, FUKUI M, OHKUBO S, TAMAOKI T. TOMITA F: Tetrocarcins, new antitumor antibiotics. III. Antitumor activity of tetrocarcin A. J. Antibiot. (1982) 35:1033-1037.
69. NAKASHIMA T, MIURA M, HARA M: Tetrocarcin A inhibits mitochondrial functions of Bcl-2 and suppresses its antiapoptotic activity. Cancer Res. (2000) 60:1229-1235.
70. KANEKO M, NAKASHIMA T, UOSAKI Y, HARA M, IKEDA S, KANDA Y: Synthesis of tetrocarcin derivatives with specific inhibitory activity towards Bcl-2 functions. Bioorg. Med. Chem. Lett. (2001) 11:887-890.
71. DUNSHEE BR, LEBEN C, KEIT GW, STRONG FM: The isolation and properties of antimycin A. J. Am. Chem. Soc. (1949) 71:2436-2437.
72. XIA D, YU CA, KIM H et al.: Crystal structure of the cytochrome bc1 complex from bovine heart mitochondria. Science (1997) 277:60-66.
73. TZUNG SP, KIM KM, BASANEZ G et al.: Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat. Cell. Biol. (2001) 3:183-191.
74. KIM KM, GIEDT CD, BASANEZ Get al.: Biophysical characterization of recombinant human Bcl-2 and its interaction with an inhibitory ligand, antimycin A. Biochemistry (2001) 40:4911-4922.
75. WANG J-L, LIU D, ZHANG Z-J et al.: Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl. Acad. Sci. USA (2000) 97:7124-7129.
76. MILELLA M, ESTROV Z, KORNBLAU SM et al.: Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood (2002) 99:3461-3464.
77. CHEN J, FREEMAN A, LIU J, DAI Q, LEE R: The apoptotic effect of HA14-1, a Bcl-2-interacting small molecule compound, requires Bax translocation and is enhanced by PK11195. Mol. Cancer Ther. (2002) 1:981-987.
78. PEI X-Y, DAI Y, GRANT S: The proteosome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA 14-1 in multiple myeloma cells. Leukemia (2003) 17:2036-2045.
79. L. Nat. Cell Biol. (2001) 3:173-182.
80. LUGOVSKOY AA. DEGTEREV AI, Fahmy AF et al.: A novel approach for characterizing protein ligand complexes: molecular basis for specificity of small-molecule Bcl-2 inhibitors. J. Am. Chem. Soc. (2002) 124:1234-1240.
81. ENYEDY IJ, LING YL, NACRO K et al.: Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J. Med. Chem. (2001) 44:4313-4324.
82. ORNER BP, ERNST JT, HAMILTON AD: Toward proteomics: Terphenyl derivatives as structural and functional mimics of extended regions of an α-helix. J. Am. Chem. Soc. (2001) 123:5382-5383.
83. ERNST JT, KUTZKI O, DEBNATH AK, JIANG S, LU H, HAMITLON AD: Design of a protein surface antagonist based on a-helix mimicry: inhibition of gp41 assembly and viral fusion.Angew. Chem. Int. Ed. (2002) 41:278-281.
84. L-Bak peptide complex: recognition between regulators of apoptosis. Science (1997) 275:983-986.
85. L antagonist based on α -helix mimicry. J. Am. Chem. Soc. (2002) 124:11838-11839.
86. WU D: An overview of the clinical pharmacology and therapeutic potential of gossypol as a male contraceptive agents and gynaecological disease. Drugs (1989) 38:333-341.
87. RADLOFF RJ, DECK LM, ROYER RE, VANDER JAGT DL: Antiviral activities of gossypol and its derivatives against herpes simplex virus Type II. Pharmacol. Res. Commun. (1986) 18:1063-1073.
88. MONTAMAT EE, BURGOS C, GEREZ DE BURGOS NM, ROVAI LE, BLANCO A, SEGURA EL: Inhibitory action of gossypol on enzymes and growth of Trypansoma cruzi. Science (1982) 218:288-289.
89. BENHAIM P, MATHES SJ, HUNT TK, SCHEUENSTUHL H, BENZ CC: Induction of neutrophil Mac-1 integrin expression and superoxide production by the medicinal plant extract gossypol. Inflammation (1994) 18:443-458.
90. FLACK MR, PYLE RG, MULLEN NM et al.: Oral gossypol in the treatment of matastatic adrenal cancer. J. Clin. Endocrinol. Metab. (1993) 76:1019-1024.
91. BRANDES AA, PASETTO LM, MONFARDINI S: New drugs in recurrent high grade gliomas. Anitcancer Res. (2000) 20:1913-1920.
92. BUSHUNOW P, REIDENBERG MM, WASENKO J et al.: Gossypol treatment of recurrent adult malignant gliomas. J. Neurooncol. (1999) 42:79-86.
93. VAN POZNAK C, SEIDMAN AD, REIDENBERG MM et al.: Oral gossypol in the treatment of patients with refractory matastatic breast cancer: a Phase I/II clinical trial. Breast Cancer Res. Treat. (2001) 66:239-248.
94. WANG X, WANG J, WONG SCH et al.: Cytotoxic effect of gossypol on colon carcinoma cells. Life Sci. (2000) 67:2663-2671.
95. ZHANG M, LIU H, GUO R et al.: Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. Biochem. Pharmacol. (2003) 66:93-103.
96. CHMURA SJ, MAUCERI H, ADVANI S et al.: Decreasing the apoptotic threshold of tumor cells through protein kinase C inhibition and sphingomyelinase activation increases tumor killing by ionizing radiation. Cancer Res. (1997) 57:4340-4347.
97. CHMURA SJ, DOLAN ME, CHA A et al.: In vitro and in vivo activity of protein kinase C inhibitor chelerythrine chloride induces tumor cell toxicity and growth delay in vivo. Clin. Cancer Res. (2000) 6:737-742.
98. L function. J. Biol. Chem. (2003) 278:20453-20456.
99. POLLMAN MJ, HALL JL, MANN MJ, ZHANG L, GIBBONS GH: Inhibition of neointimal cell Bcl-X expression induces apoptosis and regression of vascular disease. Nat. Med. (1998) 4:222-227.